2901
|
Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2016; 87:1005-15. [PMID: 27113605 PMCID: PMC5013123 DOI: 10.1136/jnnp-2015-312601] [Citation(s) in RCA: 194] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Accepted: 02/06/2016] [Indexed: 01/01/2023]
Abstract
OBJECTIVE Antibodies to cell surface central nervous system proteins help to diagnose conditions which often respond to immunotherapies. The assessment of antibody assays needs to reflect their clinical utility. We report the results of a multicentre study of aquaporin (AQP) 4 antibody (AQP4-Ab) assays in neuromyelitis optica spectrum disorders (NMOSD). METHODS Coded samples from patients with neuromyelitis optica (NMO) or NMOSD (101) and controls (92) were tested at 15 European diagnostic centres using 21 assays including live (n=3) or fixed cell-based assays (n=10), flow cytometry (n=4), immunohistochemistry (n=3) and ELISA (n=1). RESULTS Results of tests on 92 controls identified 12assays as highly specific (0-1 false-positive results). 32 samples from 50 (64%) NMO sera and 34 from 51 (67%) NMOSD sera were positive on at least two of the 12 highly specific assays, leaving 35 patients with seronegative NMO/spectrum disorder (SD). On the basis of a combination of clinical phenotype and the highly specific assays, 66 AQP4-Ab seropositive samples were used to establish the sensitivities (51.5-100%) of all 21 assays. The specificities (85.8-100%) were based on 92 control samples and 35 seronegative NMO/SD patient samples. CONCLUSIONS The cell-based assays were most sensitive and specific overall, but immunohistochemistry or flow cytometry could be equally accurate in specialist centres. Since patients with AQP4-Ab negative NMO/SD require different management, the use of both appropriate control samples and defined seronegative NMOSD samples is essential to evaluate these assays in a clinically meaningful way. The process described here can be applied to the evaluation of other antibody assays in the newly evolving field of autoimmune neurology.
Collapse
Affiliation(s)
- Patrick Waters
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Markus Reindl
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Albert Saiz
- Neuroimmunology Program, Hospital Clinic and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
| | - Kathrin Schanda
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Friederike Tuller
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Vlastimil Kral
- Zdravotni ustav se sidlem v Usti nad Labem, Centrum imunologie a mikrobiologie, Usti nad Labem, Czech Republic
| | - Petra Nytrova
- Department of Neurology, Center of Clinical Neuroscience First Faculty of Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - Ondrej Sobek
- Laboratory for CSF and Neuroimmunology, Topelex Ltd, Prague, Czech Republic
| | | | - Torben Barington
- Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
| | - Søren T Lillevang
- Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
| | - Zsolt Illes
- Institute of Clinical Research, University of Southern Denmark, Odense, Denmark Department of Neurology, University of Pécs, Pécs, Hungary
| | | | - Achim Berthele
- Klinikum rechts der Isar der TU München, Klinik für Neurologie, Munich, Germany
| | - Tímea Berki
- Department of Immunology and Biotechnology, University of Pécs, Pécs, Hungary
| | - Letizia Granieri
- Clinical Neurobiology Unit, Neuroscience Institute Cavalieri Ottolenghi (NICO), University Hospital San Luigi Gonzaga, Regional Referring Multiple Sclerosis Centre, Orbassano, Italy
| | - Antonio Bertolotto
- Clinical Neurobiology Unit, Neuroscience Institute Cavalieri Ottolenghi (NICO), University Hospital San Luigi Gonzaga, Regional Referring Multiple Sclerosis Centre, Orbassano, Italy
| | - Bruno Giometto
- Department of Neurology, Azienda ULSS 9 Treviso, Treviso, Italy
| | - Luigi Zuliani
- Department of Neurology, Azienda ULSS 9 Treviso, Treviso, Italy
| | - Dörte Hamann
- Sanquin Diagnostic Services, Department of Immunopathology and Blood Coagulation, Amsterdam, The Netherlands
| | - E Daniëlle van Pelt
- Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands
| | - Rogier Hintzen
- Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands
| | - Romana Höftberger
- Neuroimmunology Program, Hospital Clinic and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain Institute of Neurology, Medical University of Vienna, Vienna, Austria
| | - Carme Costa
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Manuel Comabella
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Xavier Montalban
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Mar Tintoré
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Aksel Siva
- Neurology Department, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey
| | - Ayse Altintas
- Neurology Department, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey
| | - Günnur Deniz
- Department of Immunology, Istanbul University, Institute of Experimental Medicine, Istanbul, Turkey
| | - Mark Woodhall
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Jacqueline Palace
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Friedemann Paul
- NeuroCure Clinical Research Center (NCRC), Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Hans-Peter Hartung
- Medical Faculty, Department of Neurology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Orhan Aktas
- Medical Faculty, Department of Neurology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - Sven Jarius
- Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Germany
| | - Brigitte Wildemann
- Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Germany
| | - Christian Vedeler
- Department of Clinical Medicine, University of Bergen, Bergen, Norway Department of Neurology, Haukeland University Hospital, Bergen, Norway
| | - Anne Ruiz
- Faculty of Medecine RTH Laennec, Lyon Neurosciences Research Centre, Neuro-inflammation and Neuro-oncology Team, Lyon, France
| | - M Isabel Leite
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Peter Trillenberg
- Department of Neurology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
| | | | | | - Angela Vincent
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Romain Marignier
- Faculty of Medecine RTH Laennec, Lyon Neurosciences Research Centre, Neuro-inflammation and Neuro-oncology Team, Lyon, France
| |
Collapse
|
2902
|
Kim JS, Cheon S, Kim SW, Kim B, Kim H, Park KD, Kim SM. Glycyrrhizic acid prevents astrocyte death by neuromyelitis optica-specific IgG via inhibition of C1q binding. Biochem Biophys Res Commun 2016; 478:553-8. [DOI: 10.1016/j.bbrc.2016.07.098] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Accepted: 07/21/2016] [Indexed: 11/15/2022]
|
2903
|
Tanaka M, Tanaka K. Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. J Neuroimmunol 2016; 298:16-8. [DOI: 10.1016/j.jneuroim.2016.06.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Revised: 06/08/2016] [Accepted: 06/13/2016] [Indexed: 10/21/2022]
|
2904
|
Jain RS, Kumar S, Mathur T, Tejwani S. Longitudinally extensive transverse myelitis: A retrospective analysis of sixty-four patients at tertiary care center of North-West India. Clin Neurol Neurosurg 2016; 148:5-12. [DOI: 10.1016/j.clineuro.2016.06.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Revised: 05/28/2016] [Accepted: 06/13/2016] [Indexed: 01/07/2023]
|
2905
|
Yokoyama K, Hori M, Yoshida A. Anti-myelin oligodendrocyte glycoprotein antibody neuritis optica following anti-NMDA receptor encephalitis. Pediatr Int 2016; 58:953-4. [PMID: 27682615 DOI: 10.1111/ped.13053] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2016] [Revised: 05/27/2016] [Accepted: 06/07/2016] [Indexed: 01/31/2023]
Affiliation(s)
- Koji Yokoyama
- Department of Pediatrics, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
| | - Mutsuki Hori
- Department of Pediatrics, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| | - Akira Yoshida
- Department of Pediatrics, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| |
Collapse
|
2906
|
Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders. Mol Neurobiol 2016; 54:5236-5242. [PMID: 27578014 DOI: 10.1007/s12035-016-0070-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Accepted: 08/18/2016] [Indexed: 02/05/2023]
Abstract
The CD40 gene is associated with many autoimmune diseases; however, there are few studies in literatures that investigate the association between CD40 and neuromyelitis optica spectrum disorders (NMOSD). This study aimed to estimate the potential association of CD40 gene polymorphisms with susceptibility to NMOSD. Four SNPs (rs1883832, rs3765459, rs4810485, and rs6074022) were selected and genotyped in a Chinese cohort comprising 162 patients with NMOSD and 237 healthy controls. P values, odds ratios (ORs), and 95 % confidential intervals (CI) for four test models (allelic, additive, dominant, and recessive) were used to assess relationships between CD40 and NMOSD. Results showed that the rs3765459 variant was significantly associated with increased risk of NMOSD in allelic model (OR = 1.48, 95 % CI 1.10-1.98, P = 0.009, P corr = 0.037), and similar results were detected in the additive and recessive models (OR = 1.47, 95 % CI 1.09-1.97, P = 0.010, P corr = 0.042; OR = 2.12, 95 % CI 1.18-3.8, P = 0.012, P corr = 0.048, respectively). Other three SNPs showed protections on NMOSD in dominant models (rs6074022, OR = 0.64, 95 % CI 0.42-0.95, P = 0.031; rs1883832, OR = 0.65, 95 % CI 0.43-0.97, P = 0.036; and rs4810485, OR = 0.63, 95 % CI 0.42-0.95, P = 0.029, respectively), but not significantly after Bonferroni corrections for multiple tests. In addition, haplotype analysis of these SNPs in tight linkage did not reveal significant association with NMOSD. This study indicates that the rs3765459 variant in CD40 gene is associated with susceptibility to NMOSD. Larger sample size studies in other ethnicities are needed to verify this association.
Collapse
|
2907
|
Yeh EA, Graves JS, Benson LA, Wassmer E, Waldman A. Pediatric optic neuritis. Neurology 2016; 87:S53-8. [PMID: 27572862 PMCID: PMC10688071 DOI: 10.1212/wnl.0000000000002822] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Accepted: 01/12/2016] [Indexed: 11/15/2022] Open
Abstract
Optic neuritis (ON) is a common presenting symptom in pediatric CNS demyelinating disorders and may be associated with dramatic visual loss. Knowledge regarding clinical presentation, associated diseases, therapy, and outcomes in ON in children has grown over the past decade. These studies have shown that younger children (<10 years of age) are more likely to present with bilateral ON and older children with unilateral ON. Furthermore, studies focusing on visual recovery have shown excellent recovery of high-contrast visual acuity in the majority of children, but functional and structural studies have shown evidence of irreversible injury and functional decline after ON in children. Although randomized controlled treatment trials have not been performed in children and adolescents with ON, standard of care suggests that the use of high-dose pulse steroids is safe and likely effective. This article reviews current knowledge about the clinical presentation and management of pediatric ON, with attention to associated syndromes and evaluative tools that may inform diagnosis and interventions.
Collapse
Affiliation(s)
- E Ann Yeh
- From the Division of Neurology (E.A.Y.), Hospital for Sick Children, Hospital for Sick Children Research Institute, Department of Pediatrics, University of Toronto, Ontario, Canada; Department of Neurology (J.S.G.), University of California, San Francisco; Department of Neurology (L.A.B.), Boston Children's Hospital, Boston, MA; Department of Neurology (E.W.), Birmingham Children's Hospital, Birmingham, UK; and Department of Neurology (A.W.), The Children's Hospital of Philadelphia, PA.
| | - Jennifer S Graves
- From the Division of Neurology (E.A.Y.), Hospital for Sick Children, Hospital for Sick Children Research Institute, Department of Pediatrics, University of Toronto, Ontario, Canada; Department of Neurology (J.S.G.), University of California, San Francisco; Department of Neurology (L.A.B.), Boston Children's Hospital, Boston, MA; Department of Neurology (E.W.), Birmingham Children's Hospital, Birmingham, UK; and Department of Neurology (A.W.), The Children's Hospital of Philadelphia, PA
| | - Leslie A Benson
- From the Division of Neurology (E.A.Y.), Hospital for Sick Children, Hospital for Sick Children Research Institute, Department of Pediatrics, University of Toronto, Ontario, Canada; Department of Neurology (J.S.G.), University of California, San Francisco; Department of Neurology (L.A.B.), Boston Children's Hospital, Boston, MA; Department of Neurology (E.W.), Birmingham Children's Hospital, Birmingham, UK; and Department of Neurology (A.W.), The Children's Hospital of Philadelphia, PA
| | - Evangeline Wassmer
- From the Division of Neurology (E.A.Y.), Hospital for Sick Children, Hospital for Sick Children Research Institute, Department of Pediatrics, University of Toronto, Ontario, Canada; Department of Neurology (J.S.G.), University of California, San Francisco; Department of Neurology (L.A.B.), Boston Children's Hospital, Boston, MA; Department of Neurology (E.W.), Birmingham Children's Hospital, Birmingham, UK; and Department of Neurology (A.W.), The Children's Hospital of Philadelphia, PA
| | - Amy Waldman
- From the Division of Neurology (E.A.Y.), Hospital for Sick Children, Hospital for Sick Children Research Institute, Department of Pediatrics, University of Toronto, Ontario, Canada; Department of Neurology (J.S.G.), University of California, San Francisco; Department of Neurology (L.A.B.), Boston Children's Hospital, Boston, MA; Department of Neurology (E.W.), Birmingham Children's Hospital, Birmingham, UK; and Department of Neurology (A.W.), The Children's Hospital of Philadelphia, PA
| |
Collapse
|
2908
|
Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder. Eur Radiol 2016; 27:2206-2215. [DOI: 10.1007/s00330-016-4561-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Revised: 08/01/2016] [Accepted: 08/11/2016] [Indexed: 10/21/2022]
|
2909
|
Grünewald B, Bennett JL, Toyka KV, Sommer C, Geis C. Efficacy of Polyvalent Human Immunoglobulins in an Animal Model of Neuromyelitis Optica Evoked by Intrathecal Anti-Aquaporin 4 Antibodies. Int J Mol Sci 2016; 17:E1407. [PMID: 27571069 PMCID: PMC5037687 DOI: 10.3390/ijms17091407] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Revised: 08/16/2016] [Accepted: 08/19/2016] [Indexed: 11/17/2022] Open
Abstract
Neuromyelitis Optica Spectrum Disorders (NMOSD) are associated with autoantibodies (ABs) targeting the astrocytic aquaporin-4 water channels (AQP4-ABs). These ABs have a direct pathogenic role by initiating a variety of immunological and inflammatory processes in the course of disease. In a recently-established animal model, chronic intrathecal passive-transfer of immunoglobulin G from NMOSD patients (NMO-IgG), or of recombinant human AQP4-ABs (rAB-AQP4), provided evidence for complementary and immune-cell independent effects of AQP4-ABs. Utilizing this animal model, we here tested the effects of systemically and intrathecally applied pooled human immunoglobulins (IVIg) using a preventive and a therapeutic paradigm. In NMO-IgG animals, prophylactic application of systemic IVIg led to a reduced median disease score of 2.4 on a 0-10 scale, in comparison to 4.1 with sham treatment. Therapeutic IVIg, applied systemically after the 10th intrathecal NMO-IgG injection, significantly reduced the disease score by 0.8. Intrathecal IVIg application induced a beneficial effect in animals with NMO-IgG (median score IVIg 1.6 vs. sham 3.7) or with rAB-AQP4 (median score IVIg 2.0 vs. sham 3.7). We here provide evidence that treatment with IVIg ameliorates disease symptoms in this passive-transfer model, in analogy to former studies investigating passive-transfer animal models of other antibody-mediated disorders.
Collapse
Affiliation(s)
- Benedikt Grünewald
- Hans-Berger Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
- Integrated Research and Treatment Center-Center for Sepsis Control and Care (CSCC), Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
- Department of Neurology, University Hospital Würzburg, Josef-Schneider-Straße 11, 97080 Würzburg, Germany.
| | - Jeffrey L Bennett
- Departments of Neurology and Ophthalmology, University of Colorado Denver, Aurora, CO 80045, USA.
| | - Klaus V Toyka
- Department of Neurology, University Hospital Würzburg, Josef-Schneider-Straße 11, 97080 Würzburg, Germany.
| | - Claudia Sommer
- Department of Neurology, University Hospital Würzburg, Josef-Schneider-Straße 11, 97080 Würzburg, Germany.
| | - Christian Geis
- Hans-Berger Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
- Integrated Research and Treatment Center-Center for Sepsis Control and Care (CSCC), Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
- Department of Neurology, University Hospital Würzburg, Josef-Schneider-Straße 11, 97080 Würzburg, Germany.
| |
Collapse
|
2910
|
Zhong X, Wang H, Ye Z, Qiu W, Lu Z, Li R, Shu Y, Chang Y, Hu X. Serum concentration of CD40L is elevated in inflammatory demyelinating diseases. J Neuroimmunol 2016; 299:66-69. [PMID: 27725124 DOI: 10.1016/j.jneuroim.2016.08.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Revised: 07/19/2016] [Accepted: 08/16/2016] [Indexed: 01/10/2023]
Abstract
It is believed that auto-inflammatory activity, including cellular and humoral immunity responses, especially T cell-B cell collaboration, is one of the most important components of the pathogenesis of inflammatory demyelinating disease. CD40L is critical for T cell-B cell collaboration. Actually, serum CD40L levels have been shown to increase in MS. In the present study, serum CD40L levels were measured by an enzyme-linked immunosorbent assay (ELISA) in NMO (n=27) and MS (n=19) patients and controls (n=14). We revealed elevation of CD40L in NMO patients, and discovered a correlation between CD40L and humoral immunity in inflammatory demyelinating disease.
Collapse
Affiliation(s)
- Xiaonan Zhong
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
| | - Honghao Wang
- Department of Neurology, Nangfang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China
| | - Zhiwei Ye
- Department of Emergency, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
| | - Wei Qiu
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
| | - Zhengqi Lu
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
| | - Rui Li
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
| | - Yaqing Shu
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
| | - Yanyu Chang
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
| | - Xueqiang Hu
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China.
| |
Collapse
|
2911
|
Netravathi M, Saini J, Mahadevan A, Hari-Krishna B, Yadav R, Pal PK, Satishchandra P. Is pruritus an indicator of aquaporin-positive neuromyelitis optica? Mult Scler 2016; 23:810-817. [DOI: 10.1177/1352458516665497] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Background: Recently, pruritus has been recognised as an important association with neuromyelitis optica spectrum disorders (NMOSD). Objective: To determine the clinical and radiological characteristics of patients with NMOSD and pruritus. Methods and results: Among 57 consecutive patients with NMOSD, 15 (26.3% women) reported pruritus. All had aquaporin-4 (AQP4) antibodies. The mean age was 34.5 ± 9.1 years, age at onset was 31.3 ± 11.0 years and the duration of illness was 3.9 ± 3.1 years. Pruritus preceded the neurological disturbances in all the patients. Predominant patients experienced pruritus in the cervical dermatome (66.7%) followed by cervicothoracic region (13.3%), trigeminal nerve (13.3%) and lumbar region (6.7%). Lesions extending from cervicomedullary junction up to the thoracic segment was the most common site of affection (40%) followed by cervicothoracic (26.7%), cervicomedullary junction to cervical cord (13.3%), cervical cord (6.7%) and thoracic segment (6.7%). Conclusion: This report is one of the largest series reporting the close association of pruritus with onset of neurological symptoms in NMOSD. It highlights the importance of recognising this rare symptom which may help in making a correct diagnosis in a patient with suspected demyelinating disorder. In a patient with NMOSD, early treatment with immunomodulation during pruritus may prevent or minimise occurrence of neurological dysfunction.
Collapse
Affiliation(s)
- Manjunath Netravathi
- Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore, India
| | - Jitender Saini
- Department of Neuroimaging & Interventional Radiology (NIIR), National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore, India
| | - Anita Mahadevan
- Department of Neuropathology, National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore, India
| | - Bollampalli Hari-Krishna
- Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore, India
| | - Ravi Yadav
- Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore, India
| | - Pramod Kumar Pal
- Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore, India
| | | |
Collapse
|
2912
|
Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, Guerrero-Zamora AM, Sola-Valls N, Ortiz-Perez S, Villoslada P, Sanchez-Dalmau B, Saiz A. Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord 2016; 9:436-40. [PMID: 27582898 DOI: 10.1177/1756285616655264] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Affiliation(s)
- Elena H Martinez-Lapiscina
- Center of Neuroimmunology and Service of Neurology, August Pi Sunyer Institute of Biomedical Research, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Maria Sepulveda
- Center of Neuroimmunology and Service of Neurology, August Pi Sunyer Institute of Biomedical Research, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Ruben Torres-Torres
- Service of Ophthalmology, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Salut Alba-Arbalat
- Center of Neuroimmunology and Service of Neurology, August Pi Sunyer Institute of Biomedical Research, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Sara Llufriu
- Center of Neuroimmunology and Service of Neurology, August Pi Sunyer Institute of Biomedical Research, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Yolanda Blanco
- Center of Neuroimmunology and Service of Neurology, August Pi Sunyer Institute of Biomedical Research, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Ana M Guerrero-Zamora
- Center of Neuroimmunology and Service of Neurology, August Pi Sunyer Institute of Biomedical Research, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Nuria Sola-Valls
- Center of Neuroimmunology and Service of Neurology, August Pi Sunyer Institute of Biomedical Research, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Santiago Ortiz-Perez
- Service of Ophthalmology, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Pablo Villoslada
- Center of Neuroimmunology and Service of Neurology, August Pi Sunyer Institute of Biomedical Research, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Bernardo Sanchez-Dalmau
- Service of Ophthalmology, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Albert Saiz
- Center of Neuroimmunology and Service of Neurology, August Pi Sunyer Institute of Biomedical Research, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| |
Collapse
|
2913
|
Etiological, clinical, and radiological features of longitudinally extensive myelopathy in Chinese patients. J Clin Neurosci 2016; 32:61-6. [PMID: 27526974 DOI: 10.1016/j.jocn.2015.12.048] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 12/21/2015] [Accepted: 12/29/2015] [Indexed: 11/20/2022]
Abstract
Longitudinally extensive myelopathy (LEM) is a rare spinal syndrome, and was mostly assessed in western populations. In order to investigate the etiological, clinical, and radiological features of LEM in Chinese patients, we retrospectively analyzed eighty-nine (40 men and 49 women, median age 45.9±15.7years) patients with LEM hospitalized in China-Japan Friendship Hospital. LEM comprised autoimmune inflammatory myelitis (n=53), metabolic and compressive disorders (n=13), vascular diseases (n=10), neoplastic diseases (n=7), infectious diseases (n=4), and syringomyelia (n=2). Neuromyelitis optica spectrum disorders (NMOSD) was the most common cause of transverse myelopathy identified in LEM (38/89 [42.7%]) characterized by intractable vomiting and hiccups and painful tonic spasms. Subacute combined degeneration and anterior spinal artery syndrome accounted for the largest non-transverse LEM, which selectively affected the spinal dorsal and/or lateral columns and the spinal anterior region, respectively. Radicular pain was common in anterior spinal artery syndrome. Postrema (n=15, 39.5%) and cervical (n=31, 81.6%) lesions were significantly increased in NMOSD versus non-NMOSD (n=7, 13.7% and n=34, 66.7%, respectively, p<0.05]. Axial T2-weighted MRI indicated that 46 (51.7%) patients exhibited complete lesions; 43 (48.3%) patients exhibited non-transverse lesions, mainly unilateral or symmetrical tract lesions. Twenty-four (51.1%) LEM patients exhibited distinct gadolinium contrast enhancement. In this Chinese cohort, LEM was primarily attributed to NMOSD. While the etiological distribution in the non-NMOSD group was different from western populations, clinical and imaging features may facilitate a differential diagnosis.
Collapse
|
2914
|
Leary S, Giovannoni G, Howard R, Miller D, Thompson A. Multiple Sclerosis and Demyelinating Diseases. Neurology 2016. [DOI: 10.1002/9781118486160.ch11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | | | | | - Alan Thompson
- National Hospital for Neurology & Neurosurgery
- UCL Institute of Neurology
| |
Collapse
|
2915
|
Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG. Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurol 2016; 15:967-981. [DOI: 10.1016/s1474-4422(16)30043-6] [Citation(s) in RCA: 80] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 04/02/2016] [Accepted: 04/11/2016] [Indexed: 02/06/2023]
|
2916
|
Lechner C, Baumann M, Hennes EM, Schanda K, Marquard K, Karenfort M, Leiz S, Pohl D, Venkateswaran S, Pritsch M, Koch J, Schimmel M, Häusler M, Klein A, Blaschek A, Thiels C, Lücke T, Gruber-Sedlmayr U, Kornek B, Hahn A, Leypoldt F, Sandrieser T, Gallwitz H, Stoffels J, Korenke C, Reindl M, Rostásy K. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 2016; 87:897-905. [PMID: 26645082 DOI: 10.1136/jnnp-2015-311743] [Citation(s) in RCA: 87] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 11/11/2015] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To determine the frequency and clinical-radiological associations of antibodies to myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) in children presenting with neuromyelitis optica (NMO) and limited forms. METHODS Children with a first event of NMO, recurrent (RON), bilateral ON (BON), longitudinally extensive transverse myelitis (LETM) or brainstem syndrome (BS) with a clinical follow-up of more than 12 months were enrolled. Serum samples were tested for MOG- and AQP4-antibodies using live cell-based assays. RESULTS 45 children with NMO (n=12), LETM (n=14), BON (n=6), RON (n=12) and BS (n=1) were included. 25/45 (56%) children had MOG-antibodies at initial presentation (7 NMO, 4 BON, 8 ON, 6 LETM). 5/45 (11%) children showed AQP4-antibodies (3 NMO, 1 LETM, 1 BS) and 15/45 (33%) were seronegative for both antibodies (2 NMO, 2 BON, 4 RON, 7 LETM). No differences were found in the age at presentation, sex ratio, frequency of oligoclonal bands or median EDSS at last follow-up between the three groups. Children with MOG-antibodies more frequently (1) had a monophasic course (p=0.018) after one year, (2) presented with simultaneous ON and LETM (p=0.004) and (3) were less likely to receive immunosuppressive therapies (p=0.0002). MRI in MOG-antibody positive patients (4) less frequently demonstrated periependymal lesions (p=0.001), (5) more often were unspecific (p=0.004) and (6) resolved more frequently (p=0.016). CONCLUSIONS 67% of all children presenting with NMO or limited forms tested positive for MOG- or AQP4-antibodies. MOG-antibody positivity was associated with distinct features. We therefore recommend to measure both antibodies in children with demyelinating syndromes.
Collapse
Affiliation(s)
- Christian Lechner
- Division of Pediatric Neurology, Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria
| | - Matthias Baumann
- Division of Pediatric Neurology, Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria
| | - Eva-Maria Hennes
- Department of Pediatric Neurology, Olgahospital Stuttgart, Stuttgart, Germany
| | - Kathrin Schanda
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Klaus Marquard
- Department of Pediatric Neurology, Olgahospital Stuttgart, Stuttgart, Germany
| | - Michael Karenfort
- Department of Pediatric Neurology, University Children's Hospital Dusseldorf, Dusseldorf, Germany
| | - Steffen Leiz
- Department of Pediatric Neurology, Children's Hospital Dritter Orden, Munich, Germany
| | - Daniela Pohl
- Division of Neurology, Children's Hospital of Eastern Ontario, Ottawa, Canada
| | | | - Martin Pritsch
- Department of Pediatric Neurology, DRK Children's Hospital Siegen, Siegen, Germany
| | - Johannes Koch
- Department of Pediatrics, Paracelsus Medical University Salzburg, Salzburg, Austria
| | - Mareike Schimmel
- Department of Pediatric Neurology, Children's Hospital Augsburg, Augsburg, Germany
| | - Martin Häusler
- Division of Neuropediatrics and Social Pediatrics, University Hospital, RWTH Aachen, Aachen, Germany
| | - Andrea Klein
- Department of Pediatric Neurology, University Children's Hospital Zurich, Zurich, Switzerland
| | - Astrid Blaschek
- Department of Pediatric Neurology and Developmental Medicine, Dr von Hauner's Children's Hospital, Ludwig Maximilian University of Munich, Munich, Germany
| | - Charlotte Thiels
- Department of Pediatric Neurology with Social Pediatrics, Children's Hospital, Ruhr University Bochum, Bochum, Germany
| | - Thomas Lücke
- Department of Pediatric Neurology with Social Pediatrics, Children's Hospital, Ruhr University Bochum, Bochum, Germany
| | | | - Barbara Kornek
- Department of Neurology, Medical University of Vienna, Vienna, Austria
| | - Andreas Hahn
- Department of Pediatric Neurology, University Children's Hospital Giessen, Giessen, Germany
| | - Frank Leypoldt
- Department of Neuroimmunology, Institute of Clinical Chemistry, Kiel, Germany Department of Neurology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
| | - Torsten Sandrieser
- Department of Pediatric Neurology, Children's Hospital Koblenz, Koblenz, Germany
| | - Helge Gallwitz
- Department of Pediatric Neurology, Children's Hospital Memmingen, Memmingen, Germany
| | - Johannes Stoffels
- Department of Pediatric Neurology, Children's Hospital Neuburg, Neuburg, Germany
| | - Christoph Korenke
- Department of Pediatric Neurology, University Children's Hospital Oldenburg, Oldenburg, Germany
| | - Markus Reindl
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Kevin Rostásy
- Department of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke, Datteln, Germany
| |
Collapse
|
2917
|
Kaivorinne AL, Lintunen J, Baumann P. Fulminant neuromyelitis optica in a Finnish woman - a case report. Clin Case Rep 2016; 4:782-5. [PMID: 27525084 PMCID: PMC4974428 DOI: 10.1002/ccr3.624] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2016] [Revised: 05/08/2016] [Accepted: 05/28/2016] [Indexed: 11/11/2022] Open
Abstract
Neuromyelitis optica is a rare inflammatory, demyelinating disease of the central nervous system that predominantly targets the optic nerves and spinal cord. Our case represents an unusual and severe course of neuromyelitis optica. Despite several forms of treatment, our patient died after a severe and short‐term attack.
Collapse
Affiliation(s)
- Anna-Lotta Kaivorinne
- Department of Neurology; Lapland Hospital District; Lapland Central Hospital; Rovaniemi Finland
| | - Janne Lintunen
- Department of Neurology; Lapland Hospital District; Lapland Central Hospital; Rovaniemi Finland
| | - Peter Baumann
- Department of Neurology; Lapland Hospital District; Lapland Central Hospital; Rovaniemi Finland
| |
Collapse
|
2918
|
Hacohen Y, Nishimoto Y, Fukami Y, Lang B, Waters P, Lim MJ, Yuki N, Vincent A. Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies. Dev Med Child Neurol 2016; 58:836-41. [PMID: 26918533 DOI: 10.1111/dmcn.13090] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/23/2015] [Indexed: 01/03/2023]
Abstract
AIM Central nervous system (CNS) autoantibodies have been reported in a range of neuroimmune diseases, but there has not been a systematic evaluation of autoantibodies in paediatric patients with brainstem encephalitis. METHOD Serum samples from 57 children (40 male, 17 female, median age 12y, range 0.6-18y) with a diagnosis of brainstem encephalitis were tested retrospectively for antibodies to GQ1b, aquaporin-4 (AQP4), myelin oligodendrocyte glycoprotein (MOG), N-methyl-D-aspartate receptor, LGI1, CASPR2, glycine receptor (GlyR), DPPX, and the voltage gated potassium channel (VGKC)-complex. RESULTS Disease localized to the brainstem was seen in 19 patients: Bickerstaff's brainstem encephalitis (n=14) and clinically isolated syndrome (n=5). Polyfocal presentation was seen in 38 children, with predominantly white matter disease in 18 patients and grey matter in 20 patients. CNS surface antibodies were found in 22/57 patients (two patients with double positivity): GQIb (n=6), NMDAR (n=7), GlyR (n=5), MOG (n=5), and one AQP4. Three patients were positive for VGKC-complex antibodies. All patients were negative for antibodies to DPPX and the VGKC-complex antigens LGI1, CASPR2, and contactin-2. Although there were some partial differences in the presentations, the clinical features and outcomes did not relate clearly to the presence or absence of specific antibodies. INTERPRETATION As determined retrospectively, 39% of patients had cell surface antibodies. The results did not suggest any relationship with treatment or outcomes obtained but it is possible that specific antibody detection could be a helpful guide to more intensive immunotherapies in some cases.
Collapse
Affiliation(s)
- Yael Hacohen
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK
| | | | - Yuki Fukami
- Department of Medicine, Yong Loo Ling School of Medicine, National University of Singapore, Singapore, Singapore
| | - Bethan Lang
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK
| | - Patrick Waters
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK
| | - Ming J Lim
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.,Children's Neurosciences, Evelina London Children's Hospital, at Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London, UK
| | - Nobuhiro Yuki
- Department of Medicine, Yong Loo Ling School of Medicine, National University of Singapore, Singapore, Singapore.,Department of Physiology, Yong Loo Ling School of Medicine, National University of Singapore, Singapore, Singapore
| | - Angela Vincent
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK
| |
Collapse
|
2919
|
Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders. Int J Mol Sci 2016; 17:ijms17081195. [PMID: 27455255 PMCID: PMC5000593 DOI: 10.3390/ijms17081195] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 07/07/2016] [Accepted: 07/19/2016] [Indexed: 01/08/2023] Open
Abstract
Detection of IgG anti-Aquaporin-4 (AQP4) in serum of patients with Neuromyelitis optica syndrome disorders (NMOSD) has improved diagnosis of these processes and differentiation from Multiple sclerosis (MS). Recent findings also claim that a subgroup of patients with NMOSD, serum negative for IgG-anti-AQP4, present antibodies anti-AQP1 instead. Explore the presence of IgG-anti-AQP1 using a previously developed cell-based assay (CBA) highly sensitive to IgG-anti-AQP4. Serum of 205 patients diagnosed as NMOSD (8), multiple sclerosis (94), optic neuritis (39), idiopathic myelitis (29), other idiopathic demyelinating disorders of the central nervous system (9), other neurological diseases (18) and healthy controls (8), were used in a CBA over fixed HEK cells transfected with hAQP1-EGFP or hM23-AQP4-EGFP, treated with Triton X-100 and untreated. ELISA was also performed. Analysis of serum with our CBA indicated absence of anti-AQP1 antibodies, whereas in cells pretreated with detergent, noisy signal made reliable detection impossible. ELISA showed positive results in few serums. The low number of NMOSD serums included in our study reduces its power to conclude the specificity of AQP1 antibodies as new biomarkers of NMOSD. Our study does not sustain detection of anti-AQP1 in serum of NMOSD patients but further experiments are expected.
Collapse
|
2920
|
Sinnecker T, Schumacher S, Mueller K, Pache F, Dusek P, Harms L, Ruprecht K, Nytrova P, Chawla S, Niendorf T, Kister I, Paul F, Ge Y, Wuerfel J. MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2016; 3:e259. [PMID: 27489865 PMCID: PMC4959510 DOI: 10.1212/nxi.0000000000000259] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/02/2016] [Accepted: 05/31/2016] [Indexed: 01/08/2023]
Abstract
Objective: To characterize paramagnetic MRI phase signal abnormalities in neuromyelitis optica spectrum disorder (NMOSD) vs multiple sclerosis (MS) lesions in a cross-sectional study. Methods: Ten patients with NMOSD and 10 patients with relapsing-remitting MS underwent 7-tesla brain MRI including supratentorial T2*-weighted imaging and supratentorial susceptibility weighted imaging. Next, we analyzed intra- and perilesional paramagnetic phase changes on susceptibility weighted imaging filtered magnetic resonance phase images. Results: We frequently observed paramagnetic rim-like (75 of 232 lesions, 32%) or nodular (32 of 232 lesions, 14%) phase changes in MS lesions, but only rarely in NMOSD lesions (rim-like phase changes: 2 of 112 lesions, 2%, p < 0.001; nodular phase changes: 2 of 112 lesions, 2%, p < 0.001). Conclusions: Rim-like or nodular paramagnetic MRI phase changes are characteristic for MS lesions and not frequently detectable in NMOSD. Future prospective studies should ask whether these imaging findings can be used as a biomarker to distinguish between NMOSD- and MS-related brain lesions.
Collapse
Affiliation(s)
- Tim Sinnecker
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Sophie Schumacher
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Katharina Mueller
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Florence Pache
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Petr Dusek
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Lutz Harms
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Klemens Ruprecht
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Petra Nytrova
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Sanjeev Chawla
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Thoralf Niendorf
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Ilya Kister
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Friedemann Paul
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Yulin Ge
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| | - Jens Wuerfel
- NeuroCure Clinical Research Center (T.S., S.S., K.M., F. Pache, F. Paul, J.W.), Clinical and Experimental Multiple Sclerosis Research Center (L.H., K.R., F. Paul), and Department of Neurology (L.H., K.R., F. Paul), Charité-Universitaetsmedizin Berlin; Institute of Neuroradiology (P.D., J.W.), Universitaetsmedizin Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience (P.D., P.N.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic; Berlin Ultrahigh Field Facility (T.N., J.W.), Max Delbrueck Center for Molecular Medicine, Berlin; Experimental and Clinical Research Center (T.N., F. Paul, J.W.), Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Department of Radiology (S.C., Y.G.), and Multiple Sclerosis Care Center, Department of Neurology (I.K.), NYU School of Medicine, New York, NY; and Medical Imaging Analysis Center AG (T.S., J.W.), Basel, Switzerland. T.S. is currently with Universitätsspital Basel, Switzerland
| |
Collapse
|
2921
|
Uzawa A, Mori M, Uchida T, Masuda H, Ohtani R, Kuwabara S. Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. Mult Scler 2016; 22:1371-5. [DOI: 10.1177/1352458515615954] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Accepted: 10/14/2015] [Indexed: 11/15/2022]
Abstract
Background: Recently, new diagnostic criteria for neuromyelitis optica spectrum disorders (NMOSD) were published. Objective: Our primary aim was to evaluate the usefulness of the new diagnostic criteria in anti-aquaporin 4 (AQP4) antibody-negative cases. Methods: Consecutive 471 patients whose anti-AQP4 antibody was measured at Chiba University were reviewed. Results: Four anti-AQP4 antibody negative-patients, who fulfilled the new diagnostic criteria for NMOSD but not 2006 diagnostic criteria for neuromyelitis optica (NMO), were identified. They showed high cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels, an absence of oligoclonal bands and/or cloud-like enhancement on magnetic resonance imaging, which are compatible findings for NMO. Conclusion: The new diagnostic criteria are clinically useful in seronegative NMOSD.
Collapse
Affiliation(s)
- Akiyuki Uzawa
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Masahiro Mori
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Tomohiko Uchida
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Hiroki Masuda
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Ryohei Ohtani
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Satoshi Kuwabara
- Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
| |
Collapse
|
2922
|
Girard B, Bonnemains C, Schmitt E, Raffo E, Bilbault C. Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease. Mult Scler 2016; 23:119-122. [PMID: 27207447 DOI: 10.1177/1352458516646087] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Metabolic and inflammatory conditions may lead to neurological disorders. Neuromyelitis optica spectrum disorders (NMOSDs) refer to a rare group of demyelinating diseases of the central nervous system which essentially involve the optic nerves and spinal cord. METHODS We report a case of biotinidase deficiency (BD) initially misdiagnosed as NMOSD in a pediatric patient. RESULTS An 8-year-old girl was initially diagnosed with NMOSD on the basis of optic neuritis (ON) associated with three episodes of longitudinally extensive transverse myelitis (LETM). Intravenous high-dose corticosteroids were effective during the first two episodes of LETM. The third acute episode which resulted in tetraplegia, respiratory distress, and blindness was refractory to corticosteroids, plasmapheresis, and rituximab. The unusual clinical course and persistent high levels of plasma and cerebrospinal fluid (CSF) lactate led to additional metabolic investigations being performed. Acylcarnitine profile revealed increased C5-OH acylcarnitine suggestive of BD. Diagnosis was confirmed by direct assessment of plasma enzyme activity (quantified as 5% of the control value). Genetic analysis revealed two mutations, c.643C>T (p.L215F) and c.1612C>T (p.R538C), in the BTD gene (3p25). Dramatic clinical improvement occurred after long-term oral biotin treatment. CONCLUSION BD is a treatable condition that may closely mimic the neurological findings of LETM and NMOSD.
Collapse
Affiliation(s)
- Barbara Girard
- Pediatric Neurology Unit, Children's Hospital, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France
| | - Chrystèle Bonnemains
- Pediatric Metabolic Unit, Children's Hospital, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France
| | - Emmanuelle Schmitt
- Pediatric Neurology Unit, Children's Hospital, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France/EA 3450 DeVAH, Faculty of Medicine, University of Lorraine, Vandoeuvre-lès-Nancy, France
| | - Emmanuel Raffo
- Diagnostic and Therapeutic Neuroradiology Department, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France
| | - Claire Bilbault
- Pediatric Neurology Unit, Children's Hospital, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France
| |
Collapse
|
2923
|
Micheva KD, Wolman D, Mensh BD, Pax E, Buchanan J, Smith SJ, Bock DD. A large fraction of neocortical myelin ensheathes axons of local inhibitory neurons. eLife 2016; 5. [PMID: 27383052 PMCID: PMC4972537 DOI: 10.7554/elife.15784] [Citation(s) in RCA: 167] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Accepted: 07/05/2016] [Indexed: 12/30/2022] Open
Abstract
Myelin is best known for its role in increasing the conduction velocity and metabolic efficiency of long-range excitatory axons. Accordingly, the myelin observed in neocortical gray matter is thought to mostly ensheath excitatory axons connecting to subcortical regions and distant cortical areas. Using independent analyses of light and electron microscopy data from mouse neocortex, we show that a surprisingly large fraction of cortical myelin (half the myelin in layer 2/3 and a quarter in layer 4) ensheathes axons of inhibitory neurons, specifically of parvalbumin-positive basket cells. This myelin differs significantly from that of excitatory axons in distribution and protein composition. Myelin on inhibitory axons is unlikely to meaningfully hasten the arrival of spikes at their pre-synaptic terminals, due to the patchy distribution and short path-lengths observed. Our results thus highlight the need for exploring alternative roles for myelin in neocortical circuits.
Collapse
Affiliation(s)
- Kristina D Micheva
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
| | - Dylan Wolman
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, United States
| | - Brett D Mensh
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, United States
| | - Elizabeth Pax
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, United States
| | - JoAnn Buchanan
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
| | - Stephen J Smith
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, United States
| | - Davi D Bock
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, United States
| |
Collapse
|
2924
|
Lin J, Xue B, Chen Z, Huang X, Pang W, Quan W, Huang Y, Li X, Xia J. Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder. Int J Neurosci 2016; 127:508-515. [DOI: 10.1080/00207454.2016.1201665] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
2925
|
Tuller F, Holzer H, Schanda K, Aboulenein-Djamshidian F, Höftberger R, Khalil M, Seifert-Held T, Leutmezer F, Berger T, Reindl M. Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders. J Neuroinflammation 2016; 13:176. [PMID: 27371173 PMCID: PMC4930584 DOI: 10.1186/s12974-016-0642-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Accepted: 06/24/2016] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND The discovery of a highly specific antibody against the aquaporin-4 (AQP4) water channel (AQP4-IgG) unified the spectrum of neuromyelitis optica spectrum disorders (NMOSD), which are considered to be antibody-mediated autoimmune diseases. The AQP4 water channel is located on astrocytic end-feet processes and consists of six transmembrane helical domains forming three extracellular loops A, C, and E in which defined amino acids were already proven to be critical for AQP4-IgG binding. However, the clinical relevance of these findings is unclear. Therefore, we have characterized the epitope specificity of AQP4-IgG-positive NMOSD patients. METHODS We established a cell-based flow cytometry assay for the quantitative detection of AQP4-IgG-positive serum samples. Human embryonic kidney (HEK) cells were transiently transfected with an EmGFP-tagged AQP4-M23, AQP4-M1, or six AQP4-M23 extracellular loop mutants including two mutations in loop A (serial AA substitution, insertion of a myc-tag), two in loop C (N153Q, insertion of a myc-tag), and two in loop E (H230G, insertion of a myc-tag). Fourty-seven baseline and 49 follow-up serum samples and six paired cerebrospinal fluid (CSF) baseline samples of 47 AQP4-IgG-positive Austrian NMOSD patients were then tested for their binding capability to AQP4-M1 and AQP4-M23 isoforms and these six extracellular loop mutants. RESULTS Overall, we could identify two broad patterns of antibody recognition based on differential sensitivity to mutations in extracellular loop A. Pattern A was characterized by reduced binding to the two mutations in loop A, whereas pattern B had only partial or no reduced binding to these mutations. These two patterns were not associated with significant differences in demographic and clinical parameters or serum titers in this retrospective study. Interestingly, we found a change of AQP4-IgG epitope recognition pattern in seven of 20 NMOSD patients with available follow-up samples. Moreover, we found different binding patterns in five of six paired CSF versus serum samples, with a predominance of pattern A in CSF. CONCLUSIONS Our study demonstrates that AQP4-IgG in sera of NMOSD patients show distinct patterns of antibody recognition. The clinical and diagnostic relevance of these findings have to be addressed in prospective studies.
Collapse
Affiliation(s)
- Friederike Tuller
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Hannah Holzer
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Kathrin Schanda
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Fahmy Aboulenein-Djamshidian
- Department of Neurology, Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Sozialmedizinisches Zentrum Ost Donauspital, Vienna, Austria
| | - Romana Höftberger
- Institute of Neurology, Medical University of Vienna, Vienna, Austria
| | - Michael Khalil
- Department of Neurology, Medical University of Graz, Graz, Austria
| | | | - Fritz Leutmezer
- Department of Neurology, Medical University of Vienna, Vienna, Austria
| | - Thomas Berger
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
| | - Markus Reindl
- Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
| |
Collapse
|
2926
|
Chuquilin M, Mullaguri N, Weinshenker B. Pediatric familial neuromyelitis optica in two sisters with long term follow-up. J Clin Neurosci 2016; 29:183-4. [DOI: 10.1016/j.jocn.2016.01.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Accepted: 01/01/2016] [Indexed: 11/27/2022]
|
2927
|
Wang X, Yi H, Liu J, Li M, Mao ZF, Xu L, Peng FH. Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders. J Neurol Sci 2016; 366:3-7. [DOI: 10.1016/j.jns.2016.04.039] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2015] [Revised: 04/01/2016] [Accepted: 04/19/2016] [Indexed: 10/21/2022]
|
2928
|
Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, Metz I, Blaschek A, Dick A, Brück W, Hohlfeld R, Meinl E, Kümpfel T. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2016; 3:e257. [PMID: 27458601 PMCID: PMC4949775 DOI: 10.1212/nxi.0000000000000257] [Citation(s) in RCA: 159] [Impact Index Per Article: 19.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 05/31/2016] [Indexed: 12/21/2022]
Abstract
Objectives: To evaluate the presence of antibodies to conformation-intact myelin oligodendrocyte glycoprotein (MOG) in a subgroup of adult patients with clinically definite multiple sclerosis (MS) preselected for a specific clinical phenotype including severe spinal cord, optic nerve, and brainstem involvement. Methods: Antibodies to MOG were investigated using a cell-based assay in 3 groups of patients: 104 preselected patients with MS (group 1), 55 age- and sex-matched, otherwise unselected patients with MS (group 2), and in 22 brain-biopsied patients with demyelinating diseases of the CNS (n = 19 with MS), 4 of whom classified as MS type II (group 3). Recognized epitopes were identified with mutated variants of MOG. Results: Antibodies to MOG were found in about 5% (5/104) of preselected adult patients with MS. In contrast, in groups 2 and 3, none of the patients tested positive for MOG antibodies. Patients with MS with antibodies to MOG predominantly manifested with concomitant severe brainstem and spinal cord involvement and had a severe disease course with high relapse rates and failure to several disease-modifying therapies. Three of them had been treated with plasma exchange with a favorable response. All anti-MOG–positive patients with MS showed typical MS lesions on brain MRI. Longitudinal analysis up to 9 years revealed fluctuations and reappearance of anti-MOG reactivity. Epitope mapping indicated interindividual heterogeneity, yet intraindividual stability of the antibody response. Conclusions: Antibodies to MOG can be found in a distinct subgroup of adult MS with a specific clinical phenotype and may indicate disease heterogeneity.
Collapse
Affiliation(s)
- Melania Spadaro
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Lisa Ann Gerdes
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Markus Krumbholz
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Birgit Ertl-Wagner
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Franziska Sabrina Thaler
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Elisabeth Schuh
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Imke Metz
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Astrid Blaschek
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Andrea Dick
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Wolfgang Brück
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Reinhard Hohlfeld
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Edgar Meinl
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| | - Tania Kümpfel
- Institute of Clinical Neuroimmunology (M.S., L.A.G., M.K., F.S.T., E.S., R.H., E.M., T.K.), Department of Radiology (B.E.-W.), and Laboratory for Immunogenetics (A.D.), Medical Campus Großhadern, Ludwig-Maximilians-Universität München; Department of Neurology (M.K.), Hertie Institut für klinische Hirnforschung, Universitätsklinikum Tübingen; Department of Neuropathology (I.M., W.B.), University Medical Center, Georg August University, Göttingen; Department of Paediatric Neurology and Developmental Medicine (A.B.), Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München; and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Munich, Germany
| |
Collapse
|
2929
|
Hayashida S, Masaki K, Yonekawa T, Suzuki SO, Hiwatashi A, Matsushita T, Watanabe M, Yamasaki R, Suenaga T, Iwaki T, Murai H, Kira JI. Early and extensive spinal white matter involvement in neuromyelitis optica. Brain Pathol 2016; 27:249-265. [PMID: 27082714 DOI: 10.1111/bpa.12386] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2016] [Accepted: 04/12/2016] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVES Studies of longitudinally extensive spinal cord lesions (LESCLs) in neuromyelitis optica (NMO) have focused on gray matter, where the relevant antigen, aquaporin-4 (AQP4), is abundant. Because spinal white matter pathology in NMO is not well characterized, we aimed to clarify spinal white matter pathology of LESCLs in NMO. METHODS We analyzed 50 spinal cord lesions from eleven autopsied NMO/NMO spectrum disorder (NMOSD) cases. We also evaluated LESCLs with three or fewer spinal cord attacks by 3-tesla MRI in 15 AQP4 antibody-positive NMO/NMOSD patients and in 15 AQP4 antibody-negative multiple sclerosis (MS) patients. RESULTS Pathological analysis revealed seven cases of AQP4 loss and four predominantly demyelinating cases. Forty-four lesions from AQP4 loss cases involved significantly more frequently posterior columns (PC) and lateral columns (LC) than anterior columns (AC) (59.1%, 63.6%, and 34.1%, respectively). The posterior horn (PH), central portion (CP), and anterior horn (AH) were similarly affected (38.6%, 36.4% and 31.8%, respectively). Isolated perivascular inflammatory lesions with selective loss of astrocyte endfoot proteins, AQP4 and connexin 43, were present only in white matter and were more frequent in PC and LC than in AC (22.7%, 29.5% and 2.3%, Pcorr = 0.020, and Pcorr = 0.004, respectively). MRI indicated LESCLs more frequently affected PC and LC than AC in anti-AQP4 antibody-seropositive NMO/NMOSD (86.7%, 60.0% and 20.0%, Pcorr = 0.005, and Pcorr = 0.043, respectively) and AQP4 antibody-seronegative MS patients (86.7%, 73.3% and 33.3%, Pcorr = 0.063, and Pcorr = 0.043, respectively). PH, CP and AH were involved in 93.3%, 86.7% and 73.3% of seropositive patients, respectively, and in 53.3%, 60.0% and 40.0% of seronegative patients, respectively. CONCLUSIONS NMO frequently and extensively affects spinal white matter in addition to central gray matter, especially in PC and LC, where isolated perivascular lesions with astrocyte endfoot protein loss may emerge. Spinal white matter involvement may also appear in early NMO, similar to cerebral white matter lesions.
Collapse
Affiliation(s)
| | | | | | | | - Akio Hiwatashi
- Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | - Hiroyuki Murai
- Neurological Therapeutics, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | |
Collapse
|
2930
|
Kong Y, Okoruwa H, Revis J, Tackley G, Leite MI, Lee M, Tracey I, Palace J. Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status. J Neurol Sci 2016; 368:84-8. [PMID: 27538606 DOI: 10.1016/j.jns.2016.06.041] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Revised: 05/22/2016] [Accepted: 06/18/2016] [Indexed: 12/30/2022]
Abstract
Pain in transverse myelitis has been poorly studied. The aim of the study was to investigate the relationship between transverse myelitis related pain and disability, quality of life, anxiety and depression, cognitive-affective states in neuromyelitis optica (NMO) patients and aquaporin4 antibody status (AQP4-Ab +ve as positive and AQP4-Ab -ve as negative). Transverse myelitis patients (44 in total; 29 AQP4-Ab +ve and 15 AQP4-Ab -ve) completed questionnaires including Pain Severity Index (PSI), Pain Catastrophising Scale (PCS), Hospital Anxiety and Depression Scale (HADS), Short Form-36 quality of life (SF-36 QOL). Clinical details such as disability, gender, age and spinal cord lesion type (short or long lesion) were noted. Correlation and multiple linear regression tests were performed using these clinical scores. Pain was found to be correlated strongly with quality of life in both groups but only correlated with disability in the AQP4-Ab +ve group. PCS, HADS and EDMUS were found to be highly correlated with pain severity using partial correlation, however, a stronger relationship between pain severity and PCS was found in the AQP4-Ab -ve group. Multiple regression analysis showed that pain severity was the most important factor for quality of life but not disability or anxiety and depression symptoms in the whole patient group. We confirm that pain is an important symptom of transverse myelitis and has more influence on quality of life than disability despite health services being predominantly focused on the latter. There may be different factors associated with pain between AQP4-Ab +ve and -ve patients.
Collapse
Affiliation(s)
- Yazhuo Kong
- Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), University of Oxford, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Helen Okoruwa
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Jon Revis
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - George Tackley
- Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), University of Oxford, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Maria Isabel Leite
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Michael Lee
- Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), University of Oxford, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Irene Tracey
- Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), University of Oxford, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Jacqueline Palace
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
| |
Collapse
|
2931
|
Peng C, Wang W, Xu Q, Zhao S, Li H, Yang M, Cao S, Zhou H, Wei S. Structural Alterations of Segmented Macular Inner Layers in Aquaporin4-Antibody-Positive Optic Neuritis Patients in a Chinese Population. PLoS One 2016; 11:e0157645. [PMID: 27336477 PMCID: PMC4919051 DOI: 10.1371/journal.pone.0157645] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2016] [Accepted: 06/02/2016] [Indexed: 12/28/2022] Open
Abstract
Objectives This study aimed to analyse the structural injury of the peripapillary retinal nerve fibre layer (pRNFL) and segmented macular layers in optic neuritis (ON) in aquaporin4-antibody (AQP4-Ab) seropositivity(AQP4-Ab-positiveON) patients and in AQP4-Ab seronegativity (AQP4-Ab-negative ON) patients in order to evaluate their correlations with the best-corrected visual acuity (BCVA) and the value of the early diagnosis of neuromyelitis optica (NMO). Design This is a retrospective, cross-sectional and control observational study. Methods In total, 213 ON patients (291 eyes) and 50 healthy controls (HC) (100 eyes) were recruited in this study. According to a serum AQP4-Ab assay, 98 ON patients (132 eyes) were grouped as AQP4-Ab-positive ON and 115 ON patients (159 eyes) were grouped as AQP4-Ab-negative ON cohorts. All subjects underwent scanning with spectralis optical coherence tomography (OCT) and BCVA tests. pRNFL and segmented macular layer measurements were analysed. Results The pRNFL thickness in AQP4-Ab-positive ON eyes showed a more serious loss during 0–2 months (-27.61μm versus -14.47 μm) and ≥6 months (-57.91μm versus -47.19μm) when compared with AQP4-Ab-negative ON eyes. AQP4-Ab-positive ON preferentially damaged the nasal lateral pRNFL. The alterations in the macular ganglion cell layer plus the inner plexiform layer (GCIP) in AQP4-Ab-positive ON eyes were similar to those in AQP4-Ab-negative ON eyes. AQP4-Ab-positive ON eyes had entirely different injury patterns in the inner nuclear layer (INL) compared with AQP4-Ab-negative ON eyes during the first 6 months after the initial ON attack. These differences were as follows: the INL volume of AQP4-Ab-positive ON eyes had a gradual growing trend compared with AQP4-Ab-negative ON eyes, and it increased rapidly during 0–2 months, reached its peak during 2–4 months, and then decreased gradually. The pRNFL and GCIP in AQP4-Ab-positive ON eyes had positive correlations with BCVA. When the pRNFL thickness decreased to 95%CI (50.77μmto 60.85μm) or when the GCIP volume decreased to 95%CI (1.288 mm3to 1.399 mm3), BCVA began to be irreversibly damaged. Conclusion The structural alterations of pRNFL and GCIP could indicate the resulting visual damage. In addition, the injury pattern of INL could be a potential structural marker to predict the conversion of ON to NMO.
Collapse
Affiliation(s)
- Chunxia Peng
- Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China
| | - Wei Wang
- Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
| | - Quangang Xu
- Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China
- Department of Neurology, Chinese PLA General Hospital, Beijing, China
| | - Shuo Zhao
- Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China
| | - Hongyang Li
- Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Mo Yang
- Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China
| | - Shanshan Cao
- Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China
| | - Huanfen Zhou
- Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China
| | - Shihui Wei
- Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China
- * E-mail:
| |
Collapse
|
2932
|
Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. J Neurol Sci 2016; 367:375-9. [PMID: 27423624 DOI: 10.1016/j.jns.2016.06.036] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2016] [Revised: 06/15/2016] [Accepted: 06/16/2016] [Indexed: 11/22/2022]
Abstract
BACKGROUND Both neuromyelitis optica spectrum disorder (NMOsd) and multiple sclerosis (MS) patients experience optic neuritis (ON) attacks characterized by rapidly reduced best-correct visual acuity (BCVA) and slow recovery. Prognosis and effects of recurrence on recovery may differ between disorders but remain unclear. OBJECTIVE To compare ON severity, time and degree of recovery and effects of previous ON between NMOsd and MS patients. METHODS Retrospective chart review was performed. BCVA measurements acquired before ON, at nadir and during recovery were retrospectively reviewed. Records were obtained on 69 ON attacks in 36 NMOsd patients and 43 attacks in 28 MS patients, including first episodes and recurrences. RESULTS NMOsd patients exhibited significantly lower BCVA values at all time points after attack (P<0.05), reached nadir earlier (P=0.014) and regained a smaller fraction of baseline BCVA than MS patients (P<0.001). In NMOsd, relapsed ON resulted in worse recovery and tended to reach nadir earlier than first-episode ON (P=0.030 and 0.059, respectively). In MS, relapsed ON also reached nadir earlier (P=0.042); however, there was no difference in recovery. CONCLUSIONS Recovery from ON was poorer in NMOsd than in MS and was negatively affected by previous ON attacks.
Collapse
|
2933
|
Wang JJ, Jaunmuktane Z, Mummery C, Brandner S, Leary S, Trip SA. Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. Neurology 2016; 87:229-31. [PMID: 27306633 DOI: 10.1212/wnl.0000000000002844] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2016] [Accepted: 03/25/2016] [Indexed: 01/27/2023] Open
Affiliation(s)
- Justine J Wang
- From the National Hospital for Neurology & Neurosurgery, UCLH NHS Foundation Trust and UCL Institute of Neurology, London, UK
| | - Zane Jaunmuktane
- From the National Hospital for Neurology & Neurosurgery, UCLH NHS Foundation Trust and UCL Institute of Neurology, London, UK
| | - Catherine Mummery
- From the National Hospital for Neurology & Neurosurgery, UCLH NHS Foundation Trust and UCL Institute of Neurology, London, UK
| | - Sebastian Brandner
- From the National Hospital for Neurology & Neurosurgery, UCLH NHS Foundation Trust and UCL Institute of Neurology, London, UK
| | - Siobhan Leary
- From the National Hospital for Neurology & Neurosurgery, UCLH NHS Foundation Trust and UCL Institute of Neurology, London, UK
| | - S Anand Trip
- From the National Hospital for Neurology & Neurosurgery, UCLH NHS Foundation Trust and UCL Institute of Neurology, London, UK.
| |
Collapse
|
2934
|
Annovazzi P, Capobianco M, Moiola L, Patti F, Frau J, Uccelli A, Centonze D, Perini P, Tortorella C, Prosperini L, Lus G, Fuiani A, Falcini M, Martinelli V, Comi G, Ghezzi A. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. J Neurol 2016; 263:1727-35. [PMID: 27286847 DOI: 10.1007/s00415-016-8188-y] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 05/30/2016] [Accepted: 05/31/2016] [Indexed: 01/10/2023]
Abstract
Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more frequently used are 375 mg/m2/week iv for 4 weeks (RTX-A) and 1000 mg iv twice, 2 weeks apart (RTX-B). Aim of this study is to confirm RTX efficacy and safety in the treatment of NMO and to evaluate whether a most favourable dosage regimen exists. Data on RTX-treated NMO patients were collected from 13 Italian Hospitals. 73 patients (64 F), were enlisted. RTX-A was administered in 42/73 patients, RTX-B in 31/73. Median follow-up was 27 months (range 7-106). Mean relapse rate in the previous year before RTX start was 2.2 ± 1.3 for RTX-A and 2.3 ± 1.2 for RTX-B. ARR in the first year of treatment was 0.8 ± 0.9 for RTX-A and 0.2 ± 0.4 for RTX-B, in the second year of treatment was 0.9 ± 1.5 for RTX-A and 0.4 ± 0.8 for RTX-B patients (p = 0.001 for the first year, ns (0.09) for the second year). RTX-B was more effective in delaying the occurrence of a relapse (HR 2.2 (95 % IC 1.08-4.53) p = 0.02). Adverse events were described in 19/73 patients (mainly urinary tract and respiratory infections, and infusion reactions). Two deaths were reported in severely disabled patients. Though with the limitations of an observational study, our data support RTX efficacy in NMO and suggest that high dose pulses might be more effective than a more fractioned dose.
Collapse
Affiliation(s)
- Pietro Annovazzi
- Multiple Sclerosis Study Center, ASST Valle Olona, PO di Gallarate (VA), Italy.
| | - M Capobianco
- Regional MS Center, University Hospital S. Luigi Gonzaga, Orbassano (TO), Italy
| | - L Moiola
- Department of Neurology, Scientific Institute H. San Raffaele, University Vita-Salute, Milan, Italy
| | - F Patti
- Multiple Sclerosis Center, University of Catania, Catania, Italy
| | - J Frau
- Multiple Sclerosis Center, University of Catania, Catania, Italy
| | - A Uccelli
- Department of Neurosciences Ophtalmology and Genetics, University of Genoa, Genoa, Italy
| | - D Centonze
- Department of Neurology I and neurorehabilitation, IRCCS Neuromed, Pozzilli (IS), Italy
- Department of Systems Medicine, University of Tor Vergata, Rome, Italy
| | - P Perini
- Department of Neurology, AO University of Padova, Padua, Italy
| | - C Tortorella
- Departments of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
| | - L Prosperini
- Department of Neurology and Psychiatry, Sapienza University, Rome, Italy
| | - G Lus
- Department of Neurological Sciences, School of Medicine, Second University of Naples, Policlinico Federico II, Naples, Italy
| | - A Fuiani
- Department of Neurosciences, Multiple Sclerosis Unit, General Hospital, "OORR", Foggia, Italy
| | - M Falcini
- Multiple Sclerosis Center, Ospedale Misericordia e Dolce, Prato, Italy
| | - V Martinelli
- Department of Neurology, Scientific Institute H. San Raffaele, University Vita-Salute, Milan, Italy
| | - G Comi
- Multiple Sclerosis Study Center, ASST Valle Olona, PO di Gallarate (VA), Italy
- Department of Neurology, Scientific Institute H. San Raffaele, University Vita-Salute, Milan, Italy
| | - A Ghezzi
- Multiple Sclerosis Study Center, ASST Valle Olona, PO di Gallarate (VA), Italy
| |
Collapse
|
2935
|
|
2936
|
Leocani L, Rocca MA, Comi G. MRI and neurophysiological measures to predict course, disability and treatment response in multiple sclerosis. Curr Opin Neurol 2016; 29:243-53. [DOI: 10.1097/wco.0000000000000333] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
2937
|
Moghadasi AN, Altintas A. NMOSD with an unusual cerebral radiologic manifestation. Mult Scler Relat Disord 2016; 7:74-5. [PMID: 27237763 DOI: 10.1016/j.msard.2016.03.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Revised: 03/25/2016] [Accepted: 03/29/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Abdorreza Naser Moghadasi
- MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Neurology Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Ayse Altintas
- Istanbul University, Cerrahpasa Medical Faculty, Department of Neurology, Istanbul, Turkey.
| |
Collapse
|
2938
|
Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica. NEUROIMAGE-CLINICAL 2016; 11:743-750. [PMID: 27330974 PMCID: PMC4908282 DOI: 10.1016/j.nicl.2016.05.014] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 04/14/2016] [Accepted: 05/25/2016] [Indexed: 12/28/2022]
Abstract
Background The optic nerve is frequently injured in multiple sclerosis and neuromyelitis optica, resulting in visual dysfunction, which may be reflected by measures distant from the site of injury. Objective To determine how retinal nerve fiber layer as a measure of axonal health, and macular volume as a measure of neuronal health are related to changes in myelin water fraction in the optic radiations of multiple sclerosis and neuromyelitis optica participants with and without optic neuritis and compared to healthy controls. Methods 12 healthy controls, 42 multiple sclerosis (16 with optic neuritis), and 10 neuromyelitis optica participants (8 with optic neuritis) were included in this study. Optical coherence tomography assessment involved measurements of the segmented macular layers (total macular, ganglion cell layer, inner plexiform layer, and inner nuclear layer volume) and paripapillary retinal nerve fiber layer thickness. The MRI protocol included a 32-echo T2-relaxation GRASE sequence. Average myelin water fraction values were calculated within the optic radiations as a measure of myelin density. Results Multiple sclerosis and neuromyelitis optica eyes with optic neuritis history had lower retinal nerve fiber layer thickness, total macular, ganglion cell and inner plexiform layer volumes compared to eyes without optic neuritis history and controls. Inner nuclear layer volume increased in multiple sclerosis with optic neuritis history (mean = 0.99 mm3, SD = 0.06) compared to those without (mean = 0.97 mm3, SD = 0.06; p = 0.003). Mean myelin water fraction in the optic radiations was significantly lower in demyelinating diseases (neuromyelitis optica: mean = 0.098, SD = 0.01, multiple sclerosis with optic neuritis history: mean = 0.096, SD = 0.01, multiple sclerosis without optic neuritis history: mean = 0.098, SD = 0.02; F3,55 = 3.35, p = 0.03) compared to controls. Positive correlations between MRI and optical coherence tomography measures were also apparent (retinal nerve fiber layer thickness and ganglion cell layer thickness: r = 0.25, p = 0.05, total macular volume and inner plexiform layer volume: r = 0.27, p = 0.04). Conclusions The relationship between reductions in OCT measures of neuro-axonal health in the anterior visual pathway and MRI-based measures of myelin health in the posterior visual pathway suggests that these measures may be linked through bidirectional axonal degeneration. First study to assess relationship between segmented retinal layers and MRI in NMO First study to use optic radiation myelin water imaging in demyelinating diseases Inner nuclear layer thickening in MS with ON may occur independently of microcystic macular edema. Myelin density reduction in the optic radiation observed in demyelinating diseases Myelin loss may be due to subclinical MS disease activity in subjects without ON. ON may lead to retinal and optic radiation pathology via bidirectional degeneration.
Collapse
|
2939
|
Prakkamakul S, Schaefer P, Gonzalez G, Rapalino O. MRI Patterns of Isolated Lesions in the Medulla Oblongata. J Neuroimaging 2016; 27:135-143. [DOI: 10.1111/jon.12361] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Accepted: 04/13/2016] [Indexed: 12/12/2022] Open
Affiliation(s)
- Supada Prakkamakul
- Neuroradiology Division, Department of Radiology; Massachusetts General Hospital; 55 Fruit Street Boston MA
- Department of Radiology, King Chulalongkorn Memorial Hospital the Thai Red Cross Society, Faculty of Medicine; Chulalongkorn University; 1873 Rama IV Road Pathumwan Bangkok Thailand
| | - Pamela Schaefer
- Neuroradiology Division, Department of Radiology; Massachusetts General Hospital; 55 Fruit Street Boston MA
| | - Gilberto Gonzalez
- Neuroradiology Division, Department of Radiology; Massachusetts General Hospital; 55 Fruit Street Boston MA
| | - Otto Rapalino
- Neuroradiology Division, Department of Radiology; Massachusetts General Hospital; 55 Fruit Street Boston MA
| |
Collapse
|
2940
|
Ferreira JD, Caldas AC, de Sá JC, Geraldes R. Longstanding spastic paraparesis in a patient infected with hepatitis C virus and seropositive for aquaporin-4 antibody - Case report and review of the literature. Mult Scler Relat Disord 2016; 8:120-3. [PMID: 27456886 DOI: 10.1016/j.msard.2016.05.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2016] [Revised: 05/09/2016] [Accepted: 05/23/2016] [Indexed: 01/21/2023]
Abstract
Nervous system involvement in Hepatitis C virus infection (HCV) has been associated to neuro-immunological deregulation, particularly in interferon-alpha treated patients. We present a case of optic and brainstem demyelinating disorder associated with aquaporin-4 (AQP4) antibodies. A 48 year-old woman, with previous diagnosis of non-treated hepatitis C, presented with a 10-year history of long-standing gait disturbance. Neurological examination disclosed a grade 4 spastic paraparesis, lower limb hyperreflexia, right positive Hoffmann sign, bilateral Babinski sign and spastic gait only possible with bilateral support. Spinal cord magnetic resonance imaging (MRI) was normal. Brain MRI showed an asymmetric, bilateral pontine and left mesencephalic hypersignal in T2 and FLAIR, with no gadolinium enhancement. Visual evoked potential revealed bilateral pre-chiasmatic conduction delay. Blood tests showed a positive anti-HCV antibody and a positive AQP4 antibody. Cerebrospinal fluid (CSF) analysis was normal, with no oligoclonal bands. The patient started intravenous (IV) methylprednisolone followed by oral prednisolone; simultaneously, interferon-alpha and ribavirin. There was a slight clinical improvement within the first weeks. There are 7 cases describing association between HCV infection and central nervous system (CNS) demyelination with positive AQP4 antibody, 4 patients under interferon-α. AQP4 antibodies should be tested in patients infected with HCV and CNS demyelination.
Collapse
Affiliation(s)
- João Dias Ferreira
- Department of Neurosciences and Mental Health, Neurology, Santa Maria Hospital, CHLN, Lisbon, Portugal.
| | - Ana Castro Caldas
- Department of Neurosciences and Mental Health, Neurology, Santa Maria Hospital, CHLN, Lisbon, Portugal
| | - João Correia de Sá
- Department of Neurosciences and Mental Health, Neurology, Santa Maria Hospital, CHLN, Lisbon, Portugal
| | - Ruth Geraldes
- Department of Clinical Neurosciences, Oxford University Hospitals, Oxford, UK; Anatomy Department, Lisbon Medical School, University of Lisbon, Lisbon, Portugal
| |
Collapse
|
2941
|
Armangue T, Yeshokumar AK, Sepúlveda M, Graus F, Saiz A. Antibodies in acquired demyelinating disorders in children. ACTA ACUST UNITED AC 2016. [DOI: 10.1186/s40893-016-0008-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
2942
|
Faissner S, Nikolayczik J, Chan A, Gold R, Yoon MS, Haghikia A. Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord 2016; 9:281-6. [PMID: 27366234 DOI: 10.1177/1756285616646332] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
INTRODUCTION Neuromyelitis optica spectrum disorder (NMOSD) is a neuroinflammatory disorder of the central nervous system, distinct from multiple sclerosis by affecting predominantly the optic nerve and the spinal cord, and mediated by antibodies directed against aquaporin 4 (AQP4-ab) as a possible pathomechanistic hallmark of NMOSD. Therapeutic options include immunosuppression with steroids or B-cell-depleting agents as baseline therapies, as well as plasma exchange (PLEX) and/or immunoadsorption (IA) during relapses. Until now, data concerning the efficacy of IA alone are scarce. METHODS Visual evoked potentials (VEPs), visual acuity and changes of symptoms at relapse leading to admission in NMOSD patients (n = 10) treated with IA in a single-centre setting were evaluated retrospectively. RESULTS All patients profited from the procedure and showed an amelioration of admission symptoms. Three patients improved in visual acuity, another three patients remained stable, whereas five patients showed an improvement in VEPs. DISCUSSION In this small cohort, IA constitutes a valid therapeutic option for patients with NMOSD as an equivalent to PLEX. Analysis in larger cohorts is warranted.
Collapse
Affiliation(s)
- Simon Faissner
- Department of Neurology, St. Josef-Hospital, Ruhr-University, Gudrunstr. 56, D-44791 Bochum, Germany
| | - Johanna Nikolayczik
- Department of Neurology, St. Josef-Hospital, Ruhr-University, Bochum, Germany
| | - Andrew Chan
- Department of Neurology, St. Josef-Hospital, Ruhr-University, Bochum, Germany
| | - Ralf Gold
- Department of Neurology, St. Josef-Hospital, Ruhr-University, Bochum, Germany
| | - Min-Suk Yoon
- Department of Neurology, St. Josef-Hospital, Ruhr-University, Bochum, Germany
| | - Aiden Haghikia
- Department of Neurology, St. Josef-Hospital, Ruhr-University, Gudrunstr. 56, D-44791 Bochum, Germany
| |
Collapse
|
2943
|
Doring TM, Granado V, Rueda F, Deistung A, Reichenbach JR, Tukamoto G, Gasparetto EL, Schweser F. Quantitative Susceptibility Mapping Indicates a Disturbed Brain Iron Homeostasis in Neuromyelitis Optica - A Pilot Study. PLoS One 2016; 11:e0155027. [PMID: 27171423 PMCID: PMC4865155 DOI: 10.1371/journal.pone.0155027] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Accepted: 04/22/2016] [Indexed: 11/18/2022] Open
Abstract
Dysregulation of brain iron homeostasis is a hallmark of many neurodegenerative diseases and can be associated with oxidative stress. The objective of this study was to investigate brain iron in patients with Neuromyelitis Optica (NMO) using quantitative susceptibility mapping (QSM), a quantitative iron-sensitive MRI technique. 12 clinically confirmed NMO patients (6 female and 6 male; age 35.4y±14.2y) and 12 age- and sex-matched healthy controls (7 female and 5 male; age 33.9±11.3y) underwent MRI of the brain at 3 Tesla. Quantitative maps of the effective transverse relaxation rate (R2*) and magnetic susceptibility were calculated and a blinded ROI-based group comparison analysis was performed. Normality of the data and differences between patients and controls were tested by Kolmogorov-Smirnov and t-test, respectively. Correlation with age was studied using Spearman's rank correlation and an ANCOVA-like analysis. Magnetic susceptibility values were decreased in the red nucleus (p<0.01; d>0.95; between -15 and -22 ppb depending on reference region) with a trend toward increasing differences with age. R2* revealed significantly decreased relaxation in the optic radiations of five of the 12 patients (p<0.0001; -3.136±0.567 s(-1)). Decreased relaxation in the optic radiation is indicative for demyelination, which is in line with previous findings. Decreased magnetic susceptibility in the red nucleus is indicative for a lower brain iron concentration, a chemical redistribution of iron into less magnetic forms, or both. Further investigations are necessary to elucidate the pathological cause or consequence of this finding.
Collapse
Affiliation(s)
- Thomas Martin Doring
- Diagnostic Imaging, Diagnosticos das Americas DASA, Rio de Janeiro, RJ, Brazil
- Departamento de Radiologia, Universidade Federal de Rio de Janeiro UFRJ, Rio de Janeiro, RJ, Brazil
| | - Vanessa Granado
- Diagnostic Imaging, Diagnosticos das Americas DASA, Rio de Janeiro, RJ, Brazil
- Departamento de Radiologia, Universidade Federal de Rio de Janeiro UFRJ, Rio de Janeiro, RJ, Brazil
| | - Fernanda Rueda
- Diagnostic Imaging, Diagnosticos das Americas DASA, Rio de Janeiro, RJ, Brazil
- Departamento de Radiologia, Universidade Federal de Rio de Janeiro UFRJ, Rio de Janeiro, RJ, Brazil
| | - Andreas Deistung
- Medical Physics Group, Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Friedrich Schiller University Jena, Jena, TH, Germany
| | - Juergen R. Reichenbach
- Medical Physics Group, Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Friedrich Schiller University Jena, Jena, TH, Germany
- Michael Stifel Center for Data-driven and Simulation Science Jena, Friedrich Schiller University Jena, Jena, TH, Germany
| | - Gustavo Tukamoto
- Diagnostic Imaging, Diagnosticos das Americas DASA, Rio de Janeiro, RJ, Brazil
| | - Emerson Leandro Gasparetto
- Diagnostic Imaging, Diagnosticos das Americas DASA, Rio de Janeiro, RJ, Brazil
- Departamento de Radiologia, Universidade Federal de Rio de Janeiro UFRJ, Rio de Janeiro, RJ, Brazil
| | - Ferdinand Schweser
- Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, United States of America
- MRI Clinical and Translational Research Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, United States of America
| |
Collapse
|
2944
|
Roy U, Saini DS, Pan K, Pandit A, Ganguly G, Panwar A. Neuromyelitis Optica Spectrum Disorder with Tumefactive Demyelination mimicking Multiple Sclerosis: A Rare Case. Front Neurol 2016; 7:73. [PMID: 27242658 PMCID: PMC4862986 DOI: 10.3389/fneur.2016.00073] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 04/27/2016] [Indexed: 01/29/2023] Open
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is a diverse condition which not only encompasses isolated longitudinally extensive transverse myelitis (LETM) and optic neuritis but also includes area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy or acute diencephalic clinical syndrome, and symptomatic cerebral syndrome. Imaging may reveal periependymal lesions surrounding the ventricular system or involvement of corticospinal tracts, area postrema, diencephalon, and corpus callosum. Rarely, there may be hemispheric tumefactive lesions that enhance in a "Cloud-like" fashion on gadolinium injection unlike in tumefactive multiple sclerosis where there is incomplete ring enhancement. Here, we present a case of aquaporin-4 positive relapsing NMOSD who presented to us with recurrent episodes of paraparesis with LETM and tumefactive lesions of brain on imaging, which enhanced in an incomplete ring like pattern resembling multiple sclerosis.
Collapse
Affiliation(s)
- Ujjawal Roy
- Department of Neurology, Bangur Institute of Neurosciences, The Institute of Post-Graduate Medical Education and Research , Kolkata , India
| | - Dinesh Satyanarayan Saini
- Department of Neurology, Bangur Institute of Neurosciences, The Institute of Post-Graduate Medical Education and Research , Kolkata , India
| | - Koushik Pan
- Department of Neurology, Bangur Institute of Neurosciences, The Institute of Post-Graduate Medical Education and Research , Kolkata , India
| | - Alak Pandit
- Department of Neurology, Bangur Institute of Neurosciences, The Institute of Post-Graduate Medical Education and Research , Kolkata , India
| | - Goutam Ganguly
- Department of Neurology, Bangur Institute of Neurosciences, The Institute of Post-Graduate Medical Education and Research , Kolkata , India
| | - Ajay Panwar
- Department of Neurology, King George's Medical University , Lucknow , India
| |
Collapse
|
2945
|
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. J Neurol 2016; 263:1382-9. [PMID: 27159992 DOI: 10.1007/s00415-016-8155-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Revised: 04/26/2016] [Accepted: 04/27/2016] [Indexed: 01/04/2023]
Abstract
Little work has been performed on the long-term outcome of optic neuritis (ON) according to the status of aquaporin-4 antibody (AQP4-Ab) and long-term prognosis in older patients in China. This study retrospectively analyzed medical records in a cohort of Chinese patients with 5-year follow-up according to AQP4-Ab status and ages from January 2009 to December 2010. The clinical features, laboratory findings and risk factors for prognosis were analyzed. A total of 128 ON patients were included, 66.4 % of whom were female. The median age at onset was 36.8 years (range 18-73). Serum AQP4-Ab was positive in 45 (35.2 %) patients, with greater frequency in the female, bilateral, and recurrent ON groups (48.2, 42.5 and 53.6 %, respectively). Seropositive AQP4-Ab ON patients had worse visual recovery compared to seronegative patients (p = 0.033). The average and four quadrants of retinal nerve fiber layer (RNFL) thickness were significantly thinner in the seropositive group than in the seronegative group (p < 0.05). At 5-year follow-up, the ON recurrence rate was higher in the seropositive AQP4-Ab patients (37/45, 82.3 %) than in the seronegative patients (35/83, 42.2 %, p < 0.001). Among the seropositive patients, 40 % (18/45) developed neuromyelitis optica (NMO). Only 1.2 % (1/83) of the seronegative patients developed NMO and 4.8 % (4/83) developed to MS. Further, the multivariate analysis in seropositive AQP4-Ab patients showed that two risk factors for transverse myelitis (TM) episode were ocular pain and recurrence within 1 year. The older patients had worse visual outcome after the first episode of ON than the younger patients (p = 0.007). However, the two groups did not differ significantly with regard to prevalence of AQP4-Ab, long-term visual recovery and the risk of developing to NMO/MS.
Collapse
|
2946
|
Gupta S, Zivadinov R, Ramanathan M, Weinstock-Guttman B. Optical coherence tomography and neurodegeneration: are eyes the windows to the brain? Expert Rev Neurother 2016; 16:765-75. [PMID: 27138997 DOI: 10.1080/14737175.2016.1180978] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
INTRODUCTION Central nervous system (CNS) pathologies have ocular manifestations due to direct and/or retrograde degeneration of the visual pathways, most often related to a direct injury to the optic nerve, retinal ganglion cells and/or its surrounding cells. These ocular manifestations can be recognized and monitored by a non-invasive technique called Optical Coherence Tomography (OCT). AREAS COVERED This review article describes the OCT technique and its application in various neurological pathologies. OCT helps in the measurement of retinal nerve fiber layer thickness (RNFLT) and macular thickness which consists of retinal ganglion cells. OCT provides a near-histological level of image resolution up to 5µm by using principles of interferometry that can detect CNS inflammatory, as well as degenerative, pathologies (i.e Multiple Sclerosis, Parkinson's disease and Alzheimer's Disease etc.) at initial clinical and possibly subclinical stages. Expert Commentary: RNFLT and macular volumes measured by OCT can serve as biomarkers for early recognition and progression of a variety of neurological disease, although the specificity of these findings in clinical diagnosis requires further refinement. An early biomarker can help in an earlier therapeutic intervention and thus preventing further progression and provide the opportunity for possible regenerative interventions of the underlying disease process. With the advent of "next-generation" OCT technology an increase in use is foreseen in research as well as in clinical practice.
Collapse
Affiliation(s)
- Sahil Gupta
- a Department of Neurology , University of Alabama , Birmingham , Alabama 35294-2172 , United States
| | - Robert Zivadinov
- b Buffalo Neuroimaging analyisis Center, Jacobs School of Medicine and Biomedical Sciences , University at Buffalo , Buffalo , New York , USA
| | - Murali Ramanathan
- c Department of Pharmaceutical Sciences and Neurology , State University of New York , Buffalo , NY , USA
| | - Bianca Weinstock-Guttman
- d Jacobs MS Center for Treatment and Research, Jacobs School of Medicine and Biomedical Sciences , University at Buffalo , Buffalo , NY , USA
| |
Collapse
|
2947
|
Young V, Quaghebeur G. Transverse Myelitis and Neuromyelitis Optica Spectrum Disorders. Semin Ultrasound CT MR 2016; 37:384-95. [PMID: 27616312 DOI: 10.1053/j.sult.2016.05.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Transverse myelitis is defined as inflammation of the spinal cord, named because of its typical clinical presentation with bandlike symptoms of altered sensation or pain in a horizontal fashion-at a specific dermatome level. Radiographic patterns might vary but the idiopathic form is more frequent to present as involvement of 3-4 vertebral segments and both sides of the cord. It is now recognized that there are numerous other causes as well as the idiopathic type, with often atypical features and geographic variation. There is also increasing recognition of other forms of myelitis, particularly the longitudinally extensive manifestation with involvement of 3 or more vertebral segments. Neuromyelitis optica, one of these subtypes can be diagnosed by means of an antibody assessment. The picture is more complicated with the expansion of the description to involve neuromyelitis optica spectrum disorders, new antibodies such as myelin oligodendrocyte glycoprotein and the inclusion of an antibody-negative variant. This article describes the different entities of transverse myelitis, with a particular focus on neuromyelitis optica spectrum disorders.
Collapse
Affiliation(s)
- Victoria Young
- Department of Neuroradiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Gerardine Quaghebeur
- Department of Neuroradiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
| |
Collapse
|
2948
|
Rovira A, Auger C. Spinal Cord in Multiple Sclerosis: Magnetic Resonance Imaging Features and Differential Diagnosis. Semin Ultrasound CT MR 2016; 37:396-410. [PMID: 27616313 DOI: 10.1053/j.sult.2016.05.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Multiple sclerosis (MS) is an idiopathic inflammatory disorder of the central nervous system that affects not only the brain but also the spinal cord. In the diagnostic and monitoring process of MS, spinal cord magnetic resonance imaging (MRI) is not performed as commonly as brain MRI, mainly because of certain technical difficulties and the increase in total acquisition time. Nonetheless, spinal cord MRI findings are important to establish a prompt accurate diagnosis of MS, impart prognostic information, and provide valuable data for monitoring the disease course in certain cases. In this article, we discuss the technical aspects of spinal cord MRI, the typical MRI features of the spinal cord in MS, the clinical indications for this examination, and the differential diagnosis with other disorders that may produce similar clinical or MRI findings.
Collapse
Affiliation(s)
- Alex Rovira
- Department of Radiology, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
| | - Cristina Auger
- Department of Radiology, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain
| |
Collapse
|
2949
|
Uehara T, Beck G, Baba K, Mihara M, Okuno T, Sumi H, Nakatsuji Y, Mochizuki H. Tumefactive brain lesion with rapid cavity formation associated with anti-aquaporin-4 antibody. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2016; 3:e230. [PMID: 27144220 PMCID: PMC4841638 DOI: 10.1212/nxi.0000000000000230] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/07/2016] [Accepted: 03/16/2016] [Indexed: 12/30/2022]
Affiliation(s)
- Takuya Uehara
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Goichi Beck
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Masahito Mihara
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Tatsusada Okuno
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Hisae Sumi
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Yuji Nakatsuji
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| |
Collapse
|
2950
|
Sepúlveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, Téllez N, Midaglia L, Ariño H, Peschl P, Reindl M, Rovira A, Montalban X, Blanco Y, Dalmau J, Graus F, Saiz A. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol 2016; 263:1349-60. [PMID: 27147513 DOI: 10.1007/s00415-016-8147-7] [Citation(s) in RCA: 89] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Revised: 04/25/2016] [Accepted: 04/26/2016] [Indexed: 01/02/2023]
Abstract
The aim of this study was to report the clinical spectrum associated with antibodies to myelin oligodendrocyte glycoprotein (MOG) in adult patients, and to assess whether phenotypic variants are dependent on recognition of rodent MOG epitopes. We retrospectively analyzed the features, course and outcome of 56 patients whose samples were investigated by brain tissue immunohistochemistry and cell-based assays using human and rodent MOG. The median age at symptom onset was 37 years (range 18-70); 35 patients (63 %) were female. After a median follow-up of 43 months (range 4-554), only 14 patients (25 %) developed a neuromyelitis optica spectrum disorder (NMOSD), 27 patients (47 %) retained the initial diagnosis of isolated optic neuritis, 7 (12 %) of longitudinally extensive transverse myelitis, and 2 (4 %) of acute disseminated encephalomyelitis; 6 patients (11 %) developed atypical demyelinating syndromes (4 had relapsing episodes of short myelitis lesions which in one occurred with optic neuritis; 1 had relapsing brainstem symptoms, and 1 relapsing demyelinating encephalomyelitis). The course was frequently associated with relapses (71 %) and good outcome. Twenty-seven patients (49 %) had antibodies that recognized rodent MOG epitopes, and 9 of them (16 %) showed a myelin staining pattern in rodent tissue. Only the myelin staining pattern was linked to NMOSD (p = 0.005). In conclusion, MOG autoimmunity in adult patients associates with a clinical spectrum wider than the one expected for patients with suspected NMOSD and overall good outcome. Antibodies to rodent MOG epitopes do not associate with any phenotypic variant.
Collapse
Affiliation(s)
- Maria Sepúlveda
- Service of Neurology, Department of Neurology, Hospital Clínic, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.,Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Thaís Armangue
- Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Neuroimmunology Unit, Department of Child Neurology, Sant Joan de Déu Hospital, University of Barcelona, Esplugues de Llobregat, Barcelona, Spain
| | - Eugenia Martinez-Hernandez
- Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Georgina Arrambide
- Servei de Neurologia-Neuroimmunologia, Centre d´Esclerosi Múltiple de Catalunya (Cemcat), Vall d´Hebron Institut de Recerca, Hospital Universitari Vall d´Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Nuria Sola-Valls
- Service of Neurology, Department of Neurology, Hospital Clínic, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.,Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Lidia Sabater
- Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Nieves Téllez
- Neurology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | | | - Helena Ariño
- Service of Neurology, Department of Neurology, Hospital Clínic, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.,Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Patrick Peschl
- Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - Markus Reindl
- Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - Alex Rovira
- Magnetic Resonance Unit, Department of Radiology (IDI), Hospital Universitari Vall d´Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Xavier Montalban
- Servei de Neurologia-Neuroimmunologia, Centre d´Esclerosi Múltiple de Catalunya (Cemcat), Vall d´Hebron Institut de Recerca, Hospital Universitari Vall d´Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Yolanda Blanco
- Service of Neurology, Department of Neurology, Hospital Clínic, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.,Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Josep Dalmau
- Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.,Institució Catalana de Recerca i Estudos Avançats (ICREA), Barcelona, Spain
| | - Francesc Graus
- Service of Neurology, Department of Neurology, Hospital Clínic, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.,Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Albert Saiz
- Service of Neurology, Department of Neurology, Hospital Clínic, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain. .,Neuroimmunology Program, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| |
Collapse
|